Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (choroid plexus epithelial cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: butamben, butamben picrate, gsk2798745 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 13 Parkinson's papers of 2,877 | 0.65 |
| pathways Reactome | 2 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 2527
Sealed predictions
- TRPV4 in dopamine neurons, braak-0.21 (p 0.586) → -0.66 (p 0.054)receipt 2534
Swarm cases
receipt 2534: TRPV4 in dopamine neurons, braak
- power
- full sample -0.47 (p 0.051, n 18), 95% CI -0.77 to +0.00. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.43 (p 0.075, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.64 (p 0.0045, n 18). not the mix.
- skeptic
- leave-one-out range -0.61 to -0.40, sign flips 0; without severely affected donors -0.47 (p 0.051, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TRPV4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts